Exosome Therapy Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Exosome Therapy Market: Distribution by Type of Therapeutic, Target Indication, Therapeutic Area, Route of Administration and Geography – Trends and Global Forecasts, till 2040
報告摘要
EXOSOME THERAPY MARKET: OVERVIEW
As per Roots Analysis, the global exosome therapy market is estimated to grow from USD 32 million in the current year to USD 1,405 million by 2040, registering a CAGR of 41.1% across the forecast period.
Exosome Therapy Market: Growth and Trends
Extracellular vesicle-based therapeutics have moved from an academic curiosity to a closely watched clinical modality. Their appeal lies in target specificity, enhanced tissue regeneration and reduced systemic inflammation relative to conventional biologics, characteristics that have drawn both industry sponsors and non-industry research groups into active development programs. A review of over 200 published studies evaluating mesenchymal stem cell derived exosomes for preclinical use reported measurable benefit in more than 70% of cases, a data point that continues to anchor investor and licensing interest in the space.
The market growth momentum has been reinforced by a steady rise in investigational new drug filings since the COVID-19 pandemic, as sponsors seek regulatory clearance to move exosome candidates into human trials. For distributors and channel partners, this represents an early but fast-widening window to establish positioning ahead of the anticipated wave of clinical and commercial launches.
Growth Drivers: Factors Fueling Market Expansion
Growth in the exosome therapy market is being driven by rising disease burden across ophthalmic, dermatological, musculoskeletal, and rectal disorders. Further, expanding research and development activity... and increasing government funding directed at exosome production and characterization infrastructure. Intra-ocular administration is emerging as a particularly active route, supported by a growing body of clinical evidence in retinal and ophthalmic indications. The broader shift of pharmaceutical R&D investment toward emerging economies is expected to add further momentum, widening the addressable base for distribution and supply chain partners over the forecast period.
Market Challenges: Critical Barriers Hindering Progress
Despite favorable long-term growth, exosome therapy developers continue to face technical and commercial challenges. Weak therapy preparations, bacterial contamination risk, and the presence of non-exosomal components complicate manufacturing consistency. Further, the inherent heterogeneity of extracellular vesicles makes standardized quantification and characterization difficult across cell sources. On the commercial side, the withdrawal of seven pipeline candidates due to enrolment and funding constraints, illustrate the financing risk that stakeholders evaluating this market need to underwrite.
Exosome Therapy Market: Key Insights
The report delves into the current state of the Exosome Therapy market and identifies potential growth opportunities for distribution partners, channel intermediaries, and service integrators. Some key findings include:
• The exosome therapeutics pipeline presently features close to 120 therapeutic candidates, with more than 40% already in clinical stage development, indicating that the market's commercial inflection point is approaching faster than headline revenue figures suggest.
• Seven exosome therapies, including EXOMSC-COV19 (Dermama Biotech Lab), Dex2 (Gustave Roussy Institute) and SF-MSC-EX (Osmangazi University), are currently in advanced clinical stages, forming a near-term watchlist for licensing and distribution partners.
• Approximately 30% of pipeline candidates target oncology indications, including breast, lung, colon cancer and melanoma, positioning exosomes as an emerging targeted drug delivery vehicle in a therapeutic area that already commands significant specialty distribution infrastructure.
• More than 60 pharmaceutical companies and academic or research institutes are actively engaged in exosome therapeutic development, reflecting a fragmented, partnership-driven ecosystem well suited to distributors offering regulatory, logistics and go-to-market support.
• Strategic in-licensing activity, such as Coya Therapeutics' 2022 agreement with Carnegie Mellon University for exosome-polymer hybrid delivery technology illustrates how platform technology access is becoming a differentiator among developers, an important due-diligence signal for investors and partners alike.
• EVerZom raised EUR 10 million in a funding round to advance exosome-based biotherapies targeting inflammatory diseases and to initiate clinical development of its pipeline programs.
• Regulatory scrutiny increased around non-compliant exosome product marketing, reinforcing the importance of IND-backed clinical development pathways for commercial legitimacy in this space.
Exosome Therapy Market Segments
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Therapeutic
• Allogeneic
• Autologous
By Target Disease Indication
• Degenerative Meniscal Injury
• Dystrophic Epidermolysis Bullosa
• Fistula Perianal
• Retinitis Pigmentosa
By Therapeutic Area
• Dermatological Disorders
• Musculoskeletal Disorders
• Ophthalmic Diseases
• Rectal Disorders
By Type of Formulation
• Liquid
• Aerosol
By Route of Administration
• Fistula Tract
• Intra-articular
• Intra-ocular
By Geographical Regions
• North America
• Europe
• Asia-Pacific
• Rest of the World
Exosome Therapy Market: Key Segments
Ophthalmic Diseases Lead the Market
Based on Roots Analysis market assessment, ophthalmic diseases are expected to account for the largest share of therapeutic area revenues. This highest share is supported by a robust clinical pipeline targeting retinal and ocular surface disorders. In addition, the relatively advanced development of intra-ocular delivery platforms, which enable localized administration, improve therapeutic exposure at the target site, and reduce systemic adverse effects, supporting the highest share. Together, these advantages position ophthalmology as one of the most commercially promising applications for exosome-based therapeutics.
Intra-Ocular Route of Administration Dominates the Market
In terms of route of administration, exosome therapeutics designed for intra-ocular delivery are expected to register higher CAGR throughout the forecast period. This is primarily due to the growing focus on ophthalmic disorders, where localized ocular delivery enables higher therapeutic concentrations at the target site while minimizing systemic exposure, making it a well-suited approach for exosome-based therapies.
Oncology Dominates the Market
Based on the Roots Analysis market report, oncology dominates the market. This can be attributed to the growing focus on oncology, with nearly 30% of exosome therapeutics currently under development targeting cancers such as breast cancer, lung cancer, melanoma, and colorectal cancer. This trend reflects the increasing interest in using exosomes as targeted drug delivery vehicles. Although the segment remains in the early stages of clinical development, its robust pipeline highlights strong long-term commercial and partnership opportunities for stakeholders positioned ahead of market maturation.
Asia-Pacific Dominates the Market and Registers Higher CAGR
Based on the proprietary report, Asia-Pacific holds the highest share and is likely to remain dominant in the future. This growth is being driven by increasing investments in regenerative medicine and advanced biologics, a rapidly expanding pipeline of exosome-based therapeutics, and the growing number of clinical trials across China, Japan, South Korea, and India.
Governments across the region are strengthening support for cell and gene therapy innovation through funding initiatives, translational research programs, and evolving regulatory frameworks. These fundings initiatives will accelerate the progression of exosome candidates toward commercialization.
Moreover, the emergence of regional biomanufacturing capabilities and strategic collaborations to scale exosome production is increasing demand for specialized logistics, GMP-compliant manufacturing support, and temperature-controlled distribution networks, positioning Asia-Pacific as a key future hub for exosome therapy development and commercialization.
Example Players in Exosome Therapy Market
• Cellular Biomedicine Group
• Coya Therapeutics
• Curexsys
• EV Therapeutics
• Evox Therapeutics
• ExoCoBio
• ILIAS Biologics
• Rion
• SHIFTBIO
Expert Interview and Industry Insights
The opinions and insights presented in the full study were shaped by discussions with multiple stakeholders across the exosome therapeutics value chain. The research report features detailed transcripts of interviews held with the following industry participants:
• Chief Business Officer, Small Company, US
• Chief Business Officer, Mid-Sized Company, South Korea
• R&D and Innovation Manager, Very Small Company, Portugal
EXOSOME THERAPY MARKET: RESEARCH COVERAGE
• Market Landscape: A detailed assessment of the current pipeline, segmented by phase of development, technology platform, type of payload, derived source, target disease indication, therapeutic area, route of administration, type of therapy, dosing frequency and line of treatment, along with a profile of developer companies by year of establishment, size and headquarters location.
• Company Profiles: In-depth profiles of key exosome therapeutics developers, including company overview, product portfolio and recent developments and future outlook.
• Drug Profiles: Elaborate profiles of the leading exosome therapy candidates in the highest phase of development, including product portfolio and detailed clinical trial information.
• Clinical Trial Analysis: A detailed analysis of completed and ongoing clinical trials by trial status, registration year, sponsor type, study design, patient enrolment, age category, trial location, and geography.
• Academic Grant Analysis: An in-depth analysis of academic grants awarded for exosome therapeutics research since 2017, covering funding institute, support period, purpose of grant, recipient organization, and grant activity code.
• Global Event Analysis: An assessment of global industry events related to exosome therapeutics, by year, platform, region, active organizers, speakers, and participant profile.
• Partnerships and Collaborations: An analysis of research, licensing, manufacturing, product development, and M&A partnerships inked in this space since 2017, by partnership type, technology platform, target indication and geography.
• Funding and Investment Analysis: A detailed analysis of grant, seed, venture capital, IPO, secondary offering, and debt financing instances since 2017, by amount invested, purpose, target indication, therapeutic area, and geography.
• Start-Up Health Indexing: A proprietary Roots Analysis framework assessing start-ups by pipeline strength, pipeline maturity, indication diversity, partnership activity, and financial support.
• Case Study (Exosome Development and Manufacturing Companies): A focused assessment of service providers offering isolation, characterization, purification, engineering, and targeted delivery capabilities, segmented by scale of operation and scalability.
• Drug Failure Analysis: An analysis of exosome therapeutics that were discontinued during clinical development, by target indication, route of administration, sponsor type, and reason for failure.
• Market Sizing and Opportunity Analysis: Year-wise global and regional (North America, Europe, Asia-Pacific, Rest of the World) market projections (2029–2040) segmented by type of therapeutic, target disease indication, therapeutic area, route of administration and leading drug candidates, presented under conservative, base, and optimistic forecast scenarios.
Key Questions Answered in this Report
• What is exosome therapy and how does it compare with conventional biologic modalities?
• What is the current and future size of the exosome therapy market?
• What is the CAGR of the exosome therapy market through 2040?
• Which companies and academic institutes are leading exosome therapeutics development?
• Which target indications and therapeutic areas are expected to generate the most revenue?
• Which route of administration is likely to dominate the market, and why?
• Which region is expected to register the fastest growth, and what is driving it?
• What are the primary technical and financing risks facing exosome therapy developers?
• What opportunities exist for distributors, logistics partners and investors entering this space?
Reasons to Buy this Report
This report is designed to give distributors, channel partners, and investors a decisive analytical edge in a fast-consolidating market. Its core differentiators include:
• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates for Till 2040 are built using a hybrid methodology that cross-validates top-down macro assessments of disease burden and pipeline maturity against bottom-up, candidate-level clinical and commercial data, minimizing forecast bias.
• Comprehensive Database Cover Across 27 Chapters: Comprehensive coverage spanning market sizing, competitive landscape, clinical trial activity, academic grant funding, global events, partnerships, financing, and drug failure analysis, with dedicated regional chapters for North America, Europe, Asia-Pacific, and Rest of the World.
• Primary Research-Backed Insights: Findings are validated through direct interviews with Chief Business Officers and R&D leaders across small and mid-sized exosome developers, ensuring conclusions reflect real operating conditions rather than desk research alone.
• Six-Parameter Actionable Segmentation: Type of therapeutic, target disease indication, therapeutic area, type of formulation, route of administration and geography enable precise opportunity sizing for any go-to-market, licensing, or investment thesis.
• Three-Scenario Forecast Modeling: Conservative, base and optimistic projections account for the funding and clinical-execution risk that has historically affected early-stage exosome developers, supporting more robust investment and partnership decisions.
• Searchable Company and Grant Database: An easily searchable Excel database of all companies, academic institutes, and grant recipients active in exosome therapeutics development, purpose-built for business development and targeted outreach.
Additional Benefits
• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2 Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Exosomes
3.1.1. Types of Extracellular Vesicles
3.1.1. Potential Sources of Exosomes
3.2. Exosome Biogenesis
3.2.1. Exosome Formation and Development Process
3.2.2. Secretion of Exosomes
3.3. Applications of Exosomes
3.4. Mechanism of Exosome Therapy
3.4.1. Exosome Drug Therapy
3.4.2. Exosome RNAi Therapy
3.4.3. Exosome Immunotherapy
3.5. Advantages of Exosome Therapy
3.6. Risks and Future Perspectives Associated with Exosome Therapeutics
4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Exosome Therapeutics Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Technology Platform
4.2.3. Analysis by Type of Payload
4.2.4. Analysis by Derived Source
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Phase of Development and Therapeutic Area
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Route of Administration
4.2.10 Analysis by Area of Application
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Dosing Frequency
4.2.13. Analysis by Type of Therapy (By Method of Composition)
4.2.14. Analysis by Line of Treatment
4.3. Exosome Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Therapeutics
5. EXOSOME THERAPY: COMPANY PROFILES
5.1. Coya Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Developments and Future Outlook
5.2. Evox Therapeutics
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Curexsys
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. EV Therapeutics
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook
5.5. SHIFTBIO
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook
6. EXOSOME THERAPY: DRUG PROFILES
6.1. AEGLE Therapeutics
6.1.1. Company Overview
6.1.2. AGLE-102: Product Portfolio
6.1.2.1. AGLE-102: Clinical Trial Information
6.1.3. Recent Developments and Future Outlook
6.2. AVEM Healthcare
6.2.1. Company Overview
6.2.2. Ardoxso: Product Portfolio
6.2.2.1. Ardoxso: Clinical Trial Information
6.2.3. Recent Developments and Future Outlook
6.3. Cellular Biomedicine Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. haMPC-Exos: Product Portfolio
6.3.3.1. haMPC-Exos: Clinical Trial Information
6.3.4. hMSC-Exos: Product Portfolio
6.3.4.1. hMSC-Exos: Clinical Trial Information
6.3.5. Undisclosed Drug 1: Product Portfolio
6.3.5.1. Undisclosed Drug 1: Clinical Trial Information
6.3.6. Recent Developments and Future Outlook
6.4. OBCTCD24
6.4.1. Company Overview
6.4.2. CovenD24: Product Portfolio
6.4.2.1. CovenD24: Clinical Trial Information
6.4.3. Recent Developments and Future Outlook
6.5. ReNeuron
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Undisclosed Drug 1: Product Portfolio
6.5.3.1. Undisclosed Drug 1: Clinical Trial Information
6.5.4. Recent Developments and Future Outlook
6.6. Stem Cell Medicine
6.6.1. Company Overview
6.6.2. Undisclosed Drug 1: Product Portfolio
6.6.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Exosome Therapeutics: List of Clinical Trials
7.2.1. Analysis by Trial Status
7.2.2. Analysis by Trial Registration Year
7.2.3. Analysis by Sponsor / Collaborator
7.2.4. Analysis by Trial Registration Year and Type of Study
7.2.5. Analysis by Trial Registration Year and Trial Status
7.2.6. Analysis by Annual Number of Patients Enrolled
7.2.7. Analysis by Study Design
7.2.8. Analysis by Age Category
7.2.9. Analysis by Phase of Development and Trial Status
7.2.10. Analysis by Phase of Development and Patients Enrolled
7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials
7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.2.13. Analysis by Trial Location
7.2.14. Analysis by Trial Status and Geography
7.2.15. Analysis by Trial Status, Patients Enrolled and Geography
8. ACADEMIC GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Exosome Therapeutics: List of Academic Grants
8.3. Analysis by Year of Grants Awarded
8.4. Analysis by Amount Awarded per Year
8.5. Analysis by Type of Funding Institute Center
8.6. Analysis by Support Period
8.7. Analysis by Purpose of Grant
8.8. Word Cloud Analysis: Emerging Focus Area
8.9. Analysis by Grant Activity Code
8.10. Analysis by Location of Recipient Organizations
8.11. Popular Recipient Organizations: Analysis by Number of Grants
8.12. Popular Recipient Organizations: Analysis by Amount Awarded
8.13. Analysis by Type of Recipient Organization
8.14. Analysis by Study Section
8.15. Analysis by Type of Grant Application
8.16. Analysis by Funding Institute Center and Support Year
9. GLOBAL EVENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. List of Global Events Related to Exosomes
9.3.1. Analysis by Year of Event
9.3.2. Analysis by Event Platform
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Region
9.3.5. Most Active Organizers: Analysis by Number of Events
9.3.6. Most Active Speakers: Analysis by Number of Events
9.3.7. Most Active Industry Participants: Analysis by Number of Events
9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events
9.3.9. Analysis by Designation of Participant
9.3.10. Analysis by Affiliated Department of Participant
9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Exosome Therapeutics: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Company and Type of Partnership
10.3.5. Analysis by Type of Technology Platform
10.3.6. Analysis by Type of Partner
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Word Cloud Analysis: Emerging Focus Areas
10.3.9. Analysis by Target Disease Indication(s)
10.3.10. Analysis by Therapeutic Area
10.3.11. Analysis by Therapeutic Area and Type of Partnership
10.3.12. Regional Distribution of Partnerships
10.3.13. Distribution by Geography
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Analysis Methodology and Key Parameters
11.2. Type of Funding
11.3. Exosome Therapeutics: List of Funding Instances
11.4. Analysis by Year of Funding
11.5. Analysis by Amount Invested
11.6. Analysis by Type of Funding
11.7. Analysis by Type of Funding and Amount Invested
11.8. Analysis by Purpose of Funding
11.9. Analysis by Target Disease Indication(s)
11.10. Analysis by Therapeutic Area
11.11. Most Active Players: Analysis by Number of Funding Instances
11.12. Most Active Players: Analysis by Amount Raised
11.13. Active Investors: Analysis by Number of Funding Instances
11.14. Distribution by Geography
11.15. Summary of Funding Activity
12. START-UP HEALTH INDEXING
12.1. Analysis Methodology and Key Parameters
12.2. Analysis by Pipeline Strength
12.3. Analysis by Pipeline Maturity
12.4. Analysis by Indication Diversity
12.5. Analysis by Number of Partnerships
12.6. Analysis by Financial Support
12.7. Start-up Health Indexing: Roots Analysis Perspective
12.8. Most Active Start-ups
13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING COMPANIES
13.1. Chapter Overview
13.2. Exosome Development and Manufacturing Companies Landscape
13.2.1. Analysis by Year of Establishment
13.2.2. Analysis by Company Size
13.2.3. Analysis by Location of Headquarters
13.2.4. Analysis by Location of Headquarters and Company Size
13.3. Analysis by Type of Service(s) Offered
13.3.1. Analysis by Method of Isolation
13.3.2. Analysis by Method of Purification
13.3.3. Analysis by Method of Characterization
13.3.4. Analysis by Method of Exosome Manufacturing
13.3.5. Analysis by Scale of Operation
13.3.6. Analysis by Scalability
14. DRUG FAILURE ANALYSIS
14.1. Methodology and Key Parameters
14.2. Exosome Therapeutics: List of Failed Drug Candidates
14.2.1. Analysis by Trial Start and Discontinuation Year
14.2.2. Analysis by Trial Status of Discontinuation
14.2.3. Analysis by Target Disease Indication(s)
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Sponsor
14.2.6. Analysis by Reasons for Drug Failure
14.2.7. Word Cloud Analysis: Emerging Focus Area
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Forecast Methodology and Key Assumptions
15.2. Global Exosome Therapy Market, Till 2040
15.2.1. Exosome Therapy Market for Allogeneic Therapy, Till 2040 (USD Million)
15.2.2. Exosome Therapy Market for Autologous Therapy, Till 2040 (USD Million)
15.2.3. Exosome Therapy Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)
15.2.4. Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
15.2.5. Exosome Therapy Market for Fistula Perianal, Till 2040 (USD Million)
15.2.6. Exosome Therapy Market for Retinitis Pigmentosa, Till 2040 (USD Million)
15.2.7. Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
15.2.8. Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
15.2.9. Exosome Therapy Market for Ophthalmic Disorders, Till 2040 (USD Million)
15.2.10. Exosome Therapy Market for Rectal Disorders, Till 2040 (USD Million)
15.2.11. Fistula Tract Exosome Therapy Market, Till 2040 (USD Million)
15.2.12. Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
15.2.13. Intra-ocular Exosome Therapy Market, Till 2040 (USD Million)
15.2.14. Exosome Therapy Market Geographical Distribution, Till 2040 (USD Million)
15.2.15. Erciyes University’s Drug: Sales Forecast, Till 2040 (USD Million)
15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)
15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, Till 2040 (USD Million)
15.2.19. ReNeuron’ Drug: Sales Forecast, Till 2040 (USD Million)
16. EXECUTIVE INSIGHTS
16.1. Capricor Therapeutics
16.1.1. Company Snapshot
16.1.2. Interview Transcript: Chief Business Officer
16.2. Exogenus Therapeutics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: R&D and Innovation Manager
16.3. ILIAS Biologics
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Chief Business Officer
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 4.1 Exosome Therapeutics: Development Pipeline
Table 4.2 Exosome Therapeutics: List of Developers
Table 5.1 Codiak BioSciences: Product Portfolio
Table 5.2 Codiak BioSciences: Clinical Trial Information
Table 5.3 Recent Developments and Future Outlook
Table 5.4 Coya Therapeutics: Product Portfolio
Table 5.5 Recent Developments and Future Outlook
Table 5.6 Curexsys: Product Portfolio
Table 5.7 Recent Developments and Future Outlook
Table 5.8 EV Therapeutics: Product Portfolio
Table 5.9 Recent Developments and Future Outlook
Table 5.10 Evox Therapeutics: Product Portfolio
Table 5.11 Recent Developments and Future Outlook
Table 5.12 SHIFTBIO: Product Portfolio
Table 5.13 Recent Developments and Future Outlook
Table 6.1 AGLE-102: Product Portfolio
Table 6.2 AGLE-102: Clinical Trial Information
Table 6.1 Ardoxso: Product Portfolio
Table 6.2 Ardoxso: Clinical Trial Information
Table 6.3 Recent Developments and Future Outlook
Table 6.1 haMPC-Exos: Product Portfolio
Table 6.2 haMPC-Exos: Clinical Trial Information
Table 6.3 hMSC-Exos: Product Portfolio
Table 6.4 hMSC-Exos: Clinical Trial Information
Table 6.5 Undisclosed Drug 1: Product Portfolio
Table 6.6 Undisclosed Drug 1: Clinical Trial Information
Table 6.7 Recent Developments and Future Outlook
Table 6.1 CovenD24: Product Portfolio
Table 6.2 CovenD24: Clinical Trial Information
Table 6.1 Undisclosed Drug 1: Product Portfolio
Table 6.2 Undisclosed Drug 1: Clinical Trial Information
Table 6.1 Recent Developments and Future Outlook
Table 6.2 Undisclosed Drug 1: Product Portfolio
Table 7.1 Exosome Therapeutics: List of Clinical Trials, 2017-2022
Table 8.1 Exosome Therapeutics: List of Grants Awarded, Pre-2015-2022
Table 9.1 Exosome Therapeutics: List of Global Events, 2017-2022
Table 10.1 Exosome Therapeutics: List of Partnerships and Collaborations, 2017-2022
Table 11.1 Exosome Therapeutics: List of Funding and Investment, 2017-2022
Table 12.1 Exosome Therapeutics: List of Start-Ups, 2017-2022
Table 13.1 Case Study: List of Exosome Service Providers
Table 17.1 Exosome Therapy Market: Distribution by Phase of Development
Table 17.2 Exosome Therapy Market: Distribution by Technology Platform
Table 17.3 Exosome Therapy Market: Distribution by Derived Source
Table 17.4 Exosome Therapy Market: Distribution by Target Disease Indication(s)
Table 17.5 Exosome Therapy Market: Distribution by Therapeutic Area
Table 17.6 Exosome Therapy Market: Distribution by Route of Administration
Table 17.7 Exosome Therapy Market: Area of Application
Table 17.8 Exosome Therapy Market: Distribution by Type of Therapy
Table 17.9 Exosome Therapy Market: Distribution by Dosing Frequency
Table 17.10 Exosome Therapy Market: Distribution by Type of Therapy (By method of composition)
Table 17.11 Exosome Therapy Market: Distribution by Line of Treatment
Table 17.12 Exosome Therapeutics Developers: Distribution by Year of Establishment
Table 17.13 Exosome Therapeutics Developers: Distribution by Company Size
Table 17.14 Exosome Therapeutics Developers: Distribution by Location of Headquarters
Table 17.15 Exosome Therapeutics Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Table 17.16 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
Table 17.17 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
Table 17.18 Clinical Trials Analysis: Distribution by Trial Status
Table 17.19 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre- 2015- 2022
Table 17.20 Clinical Trials Analysis: Distribution by Sponsor / Collaborator
Table 17.21 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
Table 17.22 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
Table 17.23 Clinical Trials Analysis: Distribution by Annual Number of Patients Enrolled
Table 17.24 Clinical Trials Analysis: Distribution by Study Design
Table 17.25 Clinical Trials Analysis: Distribution by Age Group
Table 17.26 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Table 17.27 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Table 17.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.29 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.30 Clinical Trials Analysis: Distribution by Trial Location
Table 17.31 Clinical Trials Analysis: Distribution by Trial Status and Geography
Table 17.32 Clinical Trials Analysis: Distribution by Trial Status, Patients Enrolled and Geography
Table 17.33 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019-2022
Table 17.34 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
Table 17.35 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Table 17.36 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Table 17.37 Academic Grant Analysis: Distribution by Support Period
Table 17.38 Academic Grant Analysis: Distribution by Purpose of Grants
Table 17.39 Academic Grant Analysis: Distribution by Grant Activity Code
Table 17.40 Academic Grant Analysis: Distribution by Location of Recipients Organizations
Table 17.41 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number
Table 17.42 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount
Table 17.43 Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 17.44 Academic Grant Analysis: Distribution by Study Section
Table 17.45 Academic Grant Analysis: Distribution by Type of Grant Application
Table 17.46 Academic Grant Analysis: Analysis by Funding Institute Center and Support
Table 17.47 Global Events: Cumulative Half Yearly Trend, 2019-2022
Table 17.48 Global Events: Distribution by Event Platform
Table 17.49 Global Events: Distribution by Type of Event
Table 17.50 Global Events: Distribution by Region
Table 17.51 Most Active Organizers: Distribution by Number of Events
Table 17.52 Most Active Speakers: Distribution by Number of Events
Table 17.53 Most Active Industry Participants: Distribution by Number of Events
Table 17.54 Most Active Non-Industry Participants: Distribution by Number of Events
Table 17.55 Global Events: Distribution by Designation of Participant
Table 17.56 Global Events: Distribution by Affiliated Department of Participant
Table 17.57 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Table 17.58 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.59 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
Table 17.60 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
Table 17.61 Partnerships and Collaborations: Distribution by Type of Technology Platform
Table 17.62 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.63 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Table 17.64 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.65 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Table 17.66 Partnerships and Collaborations: Regional Distribution of Partnerships
Table 17.67 Partnerships and Collaborations: Distribution by Geography
Table 17.68 Funding and Investments: Year-wise Distribution by Year of Funding, 2017-2022 (USD Million)
Table 17.69 Funding and Investments: Year-wise Distribution by Amount Invested, 2017- 2022
Table 17.70 Funding and Investments: Distribution by Type of Funding
Table 17.71 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
Table 17.72 Funding and Investments: Distribution by Purpose of Funding
Table 17.73 Funding and Investments: Distribution by Target Disease Indication(s)
Table 17.74 Funding and Investments: Distribution by Therapeutic Area
Table 17.75 Most Active Players: Distribution by Number of Funding Instances
Table 17.76 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.77 Key Investors: Distribution by Number of Funding Instances
Table 17.78 Funding and Investments: Distribution by Geography
Table 17.79 Start-up Health Indexing: Distribution by Pipeline Strength
Table 17.80 Start-up Health Indexing: Distribution by Pipeline Maturity
Table 17.81 Start-up Health Indexing: Distribution by Indication Diversity
Table 17.82 Start-up Health Indexing: Distribution by Number of Partnerships
Table 17.83 Start-up Health Indexing: Distribution by Financial Support
Table 17.84 Start-up Health Indexing: Roots Analysis Perspective
Table 17.85 Most Active Start-ups
Table 17.86 Case Study: Distribution of Exosome Development and Manufacturing Companies by Year of Establishment
Table 17.87 Case Study: Distribution of Exosome Development and Manufacturing Companies by Company Size
Table 17.88 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters
Table 17.89 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters and Company Size
Table 17.90 Case Study: Distribution of Exosome Development and Manufacturing Companies by Type of Service(s) Offered
Table 17.91 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Isolation
Table 17.92 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Purification
Table 17.93 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Characterization
Table 17.94 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Manufacturing
Table 17.95 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scale of Operation
Table 17.96 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scalability
Table 17.97 Drug Failure Analysis: Distribution by Trial Start and Discontinuation Year
Table 17.98 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Table 17.99 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Table 17.100 Drug Failure Analysis: Distribution by Route of Administration
Table 17.101 Drug Failure Analysis: Distribution by Type of Sponsor
Table 17.102 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Table 17.103 Global Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.104 Exosome Therapy Market for Autologous Therapy, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.105 Exosome Therapy Market for Allogeneic Therapy, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.106 Exosome Therapy Market for Degenerative Meniscal Injury, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.107 Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.108 Exosome Therapy Market for Fistula Perianal, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.109 Exosome Therapy Market for Retinitis Pigmentosa, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.110 Exosome Therapy Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.111 Exosome Therapy Market for Muscoskeletal Disorders, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.112 Exosome Therapy Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.113 Exosome Therapy Market for Rectal Disorders, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.114 Fistula Tract Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.115 Intra-articular Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.116 Intra-ocular Exosome Therapy Market, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.117 Exosome Therapy Market Geographical Distribution, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.118 Erciyes University’s Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.119 Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2031-2040 (USD Million)
Table 17.120 AGLE-102: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2040 (USD Million)
Table 17.121 Trehan University of Medical Sciences’ Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Table 17.122 ReNeuron’ Drug: Sales Forecast, Conservative, Base and Optimistic Scenarios, Till 2040 (USD Million)
Figure 3.1 Types of Extracellular Vesicles
Figure 3.1 Potential Sources of Exosomes
Figure 3.2 Secretion of Exosomes
Figure 3.3 Mechanism of Exosome Therapy
Figure 4.1 Exosome Therapeutics: Distribution by Phase of Development
Figure 4.2 Exosome Therapeutics: Distribution by Technology Platform
Figure 4.3 Exosome Therapeutics: Distribution by Type of Payload
Figure 4.4 Exosome Therapeutics: Distribution by Derived Source
Figure 4.5 Exosome Therapeutics: Distribution by Target Disease Indication(s)
Figure 4.6 Exosome Therapeutics: Distribution by Therapeutic Area
Figure 4.7 Exosome Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 4.8 Exosome Therapeutics: Distribution by Therapeutic Area and Route of Administration
Figure 4.9 Exosome Therapeutics: Distribution by Route of Administration
Figure 4.10 Exosome Therapeutics: Area of Application
Figure 4.11 Exosome Therapeutics: Distribution by Type of Therapy
Figure 4.12 Exosome Therapeutics: Distribution by Dosing Frequency
Figure 4.13 Exosome Therapeutics: Distribution by Type of Therapy (By method of composition)
Figure 4.14 Exosome Therapeutics: Distribution by Line of Treatment
Figure 4.15 Exosome Therapy Developers: Distribution by Year of Establishment
Figure 4.16 Exosome Therapy Developers: Distribution by Company Size
Figure 4.17 Exosome Therapy Developers: Distribution by Location of Headquarters
Figure 4.18 Exosome Therapy Developers: Most Active Players: Distribution by Number of Therapeutic Programs
Figure 6.1 Cellular Biomedicine Group: Financial Information, FY 2015- FY 2019 (USD Million)
Figure 6.2 ReNeuron: Financial Information, FY 2018- FY 2022 (USD Million)
Figure 7.1 Clinical Trials Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trials Analysis: Year-wise Distribution by Trial Registration Year, Pre- 2015- 2022
Figure 7.3 Clinical Trials Analysis: Distribution by Sponsor / Collaborator
Figure 7.4 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Type of Study, Pre-2015-2022
Figure 7.5 Clinical Trials Analysis: Year-wise Distribution by Registration Year and Status of Trial, Pre-2015-2022
Figure 7.7 Clinical Trials Analysis: Distribution by Annual Number of Patients Enrolled
Figure 7.6 Clinical Trials Analysis: Distribution by Study Design
Figure 7.9 Clinical Trials Analysis: Distribution by Age Group
Figure 7.10 Clinical Trials Analysis: Distribution by Phase of Development and Trial Status
Figure 7.11 Clinical Trials Analysis: Distribution by Phase of Development and Patient Enrollment
Figure 7.12 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 7.14 Clinical Trials Analysis: Distribution by Trial Location
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status and Geography
Figure 7.15 Clinical Trials Analysis: Distribution by Trial Status, Patients Enrolled and Geography
Figure 8.1 Academic Grant Analysis: Year-wise Distribution of Number of Grants, Pre-2019-2022
Figure 8.2 Academic Grant Analysis: Year-wise Distribution by Amount of Grant Awarded, Pre-2019-2022 (USD Million)
Figure 8.3 Academic Grant Analysis: Popular NIH Departments: Analysis by Number of Grants
Figure 8.4 Academic Grant Analysis: Analysis by Type of Funding Institute Center
Figure 8.5 Academic Grant Analysis: Distribution by Support Period
Figure 8.6 Academic Grant Analysis: Distribution by Purpose of Grants
Figure 8.7 Academic Grant Analysis: Distribution by Emerging Focus Area
Figure 8.8 Academic Grant Analysis: Distribution by Grant Activity Code
Figure 8.9 Academic Grant Analysis: Distribution by Location of Recipients Organizations
Figure 8.10 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Number of Grants
Figure 8.11 Academic Grant Analysis: Popular Recipient Organizations: Analysis by Amount Awarded
Figure 8.12 Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Academic Grant Analysis: Distribution by Study Section
Figure 8.14 Academic Grant Analysis: Distribution by Type of Grant Application
Figure 8.15 Academic Grant Analysis: Analysis by Funding Institute Center and Support Year
Figure 9.1 Global Events: Cumulative Half Yearly Trend, 2019-2022
Figure 9.2 Global Events: Distribution by Event Platform
Figure 9.3 Global Events: Distribution by Type of Event
Figure 9.4 Global Events: Distribution by Region
Figure 9.6 Most Active Organizers: Distribution by Number of Events
Figure 9.7 Most Active Speakers: Distribution by Number of Events
Figure 9.8 Most Active Industry Participants: Distribution by Number of Events
Figure 9.9 Most Active Non-Industry Participants: Distribution by Number of Events
Figure 9.10 Global Events: Distribution by Designation of Participant
Figure 9.11 Global Events: Distribution by Affiliated Department of Participant
Figure 9.12 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-wise Distribution by Year and Type of Partnership, 2017- 2022
Figure 10.4 Partnerships and Collaborations: Year-wise Distribution by Company and Type of Partnership, 2017- 2022
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Technology Platform
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.7 Word Cloud Analysis: Emerging Focus Areas
Figure 10.8 Partnerships and Collaborations: Distribution by Target Disease Indication(s)
Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.10 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partnership
Figure 10.11 Partnerships and Collaborations: Regional Distribution of Partnerships
Figure 10.12 Partnerships and Collaborations: Distribution by Geography
Figure 11.1 Funding and Investments: Year-wise Distribution by Year of Funding, 2017- 2022
Figure 11.2 Funding and Investments: Year-wise Distribution by Amount Invested, 2017- 2022 (USD Million)
Figure 11.3 Funding and Investments: Distribution by Type of Funding
Figure 11.4 Funding and Investments: Year-wise Distribution by Type of Funding and Amount Invested, 2017- 2022
Figure 11.5 Funding and Investments: Distribution by Purpose of Funding
Figure 11.6 Funding and Investments: Distribution by Target Disease Indication(s)
Figure 11.7 Funding and Investments: Distribution by Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Funding Instances
Figure 11.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.10 Key Investors: Distribution by Number of Funding Instances
Figure 11.11 Funding and Investments: Distribution by Geography
Figure 11.12 Summary of Funding Instances
Figure 12.1 Start-up Health Indexing: Distribution by Pipeline Strength
Figure 12.2 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 12.2 Start-up Health Indexing: Distribution by Indication Diversity
Figure 12.5 Start-up Health Indexing: Distribution by Number of Partnerships
Figure 12.3 Start-up Health Indexing: Distribution by Financial Support
Figure 12.4 Start-up Health Indexing: Distribution by Number of Investors
Figure 12.6 Start-up Health Indexing: Roots Analysis Perspective
Figure 12.7 Most Active Start-ups
Figure 13.1 Case Study: Distribution of Exosome Development and Manufacturing Companies by Year of Establishment
Figure 13.2 Case Study: Distribution of Exosome Development and Manufacturing Companies by Company Size
Figure 13.3 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters
Figure 13.4 Case Study: Distribution of Exosome Development and Manufacturing Companies by Location of Headquarters and Company Size
Figure 13.5 Case Study: Distribution of Exosome Development and Manufacturing Companies by Type of Service(s) Offered
Figure 13.6 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Isolation
Figure 13.7 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Purification
Figure 13.8 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Characterization
Figure 13.9 Case Study: Distribution of Exosome Development and Manufacturing Companies by Method(s) of Manufacturing
Figure 13.10 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scale of Operation
Figure 13.11 Case Study: Distribution of Exosome Development and Manufacturing Companies by Scalability
Figure 14.1 Drug Failure Analysis: Distribution by Trial Start and Discontinuation Year
Figure 14.2 Drug Failure Analysis: Distribution by Trial Status of Discontinuation
Figure 14.3 Drug Failure Analysis: Distribution by Target Disease Indication(s)
Figure 14.4 Drug Failure Analysis: Distribution by Route of Administration
Figure 14.5 Drug Failure Analysis: Distribution by Type of Sponsor
Figure 14.6 Drug Failure Analysis: Distribution by Reasons for Drug Failure
Figure 15.1 Global Exosome Therapy Market, Till 2040 (USD Million)
Figure 15.2 Exosome Therapy Market for Allogeneic Therapy, 2029-240 (USD Million)
Figure 15.3 Exosome Therapy Market for Autologous Therapy, Till 2040 (USD Million)
Figure 15.4 Exosome Therapy Market for Retinitis Pigmentosa, 2031-2040 (USD Million)
Figure 15.5 Exosome Therapy Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)
Figure 15.6 Exosome Therapy Market for Degenerative Meniscal Injury, Till 2040 (USD Million)
Figure 15.7 Exosome Therapy Market for Fistula Perianal, Till 2040 (USD Million)
Figure 15.8 Exosome Therapy Market for Dermatological Disorders, 2030-2040 (USD Million)
Figure 15.9 Exosome Therapy Market for Muscoskeletal Disorders, 2031-2040 (USD Million)
Figure 15.10 Exosome Therapy Market for Ophthalmic Disorders, Till 2040 (USD Million)
Figure 15.11 Exosome Therapy Market for Rectal Disorders, Till 2040 (USD Million)
Figure 15.12 Fistula Tract Exosome Therapy Market, Till 2040 (USD Million)
Figure 15.13 Intra-articular Exosome Therapy Market, 2031-2040 (USD Million)
Figure 15.14 Intra-ocular Exosome Therapy Market, Till 2040 (USD Million)
Figure 15.15 Exosome Therapy Market Geographical Distribution, 2031-2040 (USD Million)
Figure 15.16 Erciyes University’s Drug: Sales Forecast, Till 2040 (USD Million)
Figure 15.17 Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)
Figure 15.18 AGLE-102: Sales Forecast, 2030-2040 (USD Million)
Figure 15.19 Trehan University of Medical Sciences’ Drug: Sales Forecast, Till 2040 (USD Million)
Figure 15.20 ReNeuron’ Drug: Sales Forecast, Till 2040 (USD Million)
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們